FilingReader Intelligence
Huadong Medicine subsidiary gets US FDA cancer drug approval
July 14, 2025 at 05:18 PM UTC•By FilingReader AI
Hangzhou Zhongmei Huadong Pharmaceutical, a wholly-owned subsidiary of Huadong Medicine, received US FDA approval for Phase I clinical trials of HDM2020 for injection, targeting advanced solid tumors.
The Class 1 biological new drug also gained approval for clinical trials in China in June 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:000963•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Huadong Medicine publishes news
Free account required • Unsubscribe anytime